{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:35:50Z","timestamp":1769042150681,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["18491"],"award-info":[{"award-number":["18491"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10549-021-06488-x","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:03:17Z","timestamp":1643241797000},"page":"223-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy"],"prefix":"10.1007","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-0621","authenticated-orcid":false,"given":"Danielle","family":"Rodin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinku","family":"Sutradhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Nofech-Mozes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Faught","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Trebinjac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Paszat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Rakovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"8","key":"6488_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamasurg.2015.0876","volume":"150","author":"Y Sagara","year":"2015","unstructured":"Sagara Y, Mallory MA, Wong S et al (2015) Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg 150(8):739\u2013745","journal-title":"JAMA Surg"},{"issue":"2","key":"6488_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.1998.16.2.441","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16(2):441\u2013452","journal-title":"J Clin Oncol"},{"issue":"9203","key":"6488_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(99)06341-2","volume":"355","author":"JP Julien","year":"2000","unstructured":"Julien JP, Bijker N, Fentiman IS et al (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853: EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355(9203):528\u2013533","journal-title":"Lancet"},{"issue":"32","key":"6488_CR4","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/JCO.2013.49.5077","volume":"31","author":"M Donker","year":"2013","unstructured":"Donker M, Litiere S, Werutsky G et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31(32):4054\u20134059","journal-title":"J Clin Oncol"},{"issue":"6","key":"6488_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","volume":"103","author":"IL Wapnir","year":"2011","unstructured":"Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478\u2013488","journal-title":"J Natl Cancer Inst"},{"key":"6488_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","volume":"41","author":"C Correa","year":"2010","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G, Correa C, McGale P et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 41:162\u2013177","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"12","key":"6488_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jnci\/djv263","volume":"107","author":"M Worni","year":"2015","unstructured":"Worni M, Akushevich I, Greenup R et al (2015) Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst 107(12):263","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"6488_CR8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.ejso.2016.05.024","volume":"42","author":"Mammary Fold Academic Research Collaborative","year":"2016","unstructured":"Mammary Fold Academic Research Collaborative (2016) Variation in the management of ductal carcinoma in situ in the UK: results of the Mammary fold national practice survey. Eur J Surg Oncol 42(8):1153\u20131161","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"6488_CR9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/curroncol28020130","volume":"28","author":"R Seguin","year":"2021","unstructured":"Seguin R, Peiris L (2021) National variations in the work-up, investigation, and surgical management of ductal carcinoma in situ of the breast across canadian surgeons. Curr Oncol 28(2):1366\u20131375","journal-title":"Curr Oncol"},{"issue":"6","key":"6488_CR10","first-page":"446","volume":"29","author":"SA Kaufman","year":"2015","unstructured":"Kaufman SA, Harris EE, Bailey L et al (2015) ACR appropriateness criteria(R) ductal carcinoma in situ. Oncology 29(6):446\u2013458","journal-title":"Oncology"},{"issue":"2","key":"6488_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijrobp.2018.09.022","volume":"103","author":"SN Hamilton","year":"2019","unstructured":"Hamilton SN, Nichol A, Wai E et al (2019) Local relapse after breast-conserving therapy versus mastectomy for extensive pure ductal carcinoma in situ \u22654 cm. Int J Radiat Oncol Biol Phys 103(2):381\u2013388","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"6488_CR12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L et al (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ: the LORD study. Eur J Cancer 51(12):1497\u20131510","journal-title":"Eur J Cancer"},{"key":"6488_CR13","unstructured":"Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial for low risk DCIS (COMET). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02926911. Accessed Jun 10, 2020"},{"issue":"16","key":"6488_CR14","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","volume":"51","author":"A Francis","year":"2015","unstructured":"Francis A, Thomas J, Fallowfield L et al (2015) Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 51(16):2296\u20132303","journal-title":"Eur J Cancer"},{"issue":"1","key":"6488_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-019-05364-z","volume":"178","author":"E Rakovitch","year":"2019","unstructured":"Rakovitch E, Sutradhar R, Lalani N et al (2019) Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat 178(1):169\u2013176","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6488_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djw256","volume":"109","author":"E Rakovitch","year":"2017","unstructured":"Rakovitch E, Nofech-Mozes S, Hanna W et al (2017) Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst 109(4):14","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"6488_CR17","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V","volume":"77","author":"MJ Silverstein","year":"1996","unstructured":"Silverstein MJ, Lagios MD, Craig PH et al (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77(11):2267\u20132274","journal-title":"Cancer"},{"key":"6488_CR18","doi-asserted-by":"crossref","unstructured":"Chua BH, Link E, Kunkler I, et al. A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3\u201307\/TROG 07.01). San Antonio Breast Cancer Symposium; 2021; San Antonio, Texas.","DOI":"10.1158\/1538-7445.SABCS20-GS2-04"},{"issue":"5","key":"6488_CR19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s12282-017-0765-0","volume":"24","author":"R Mercieca-Bebber","year":"2017","unstructured":"Mercieca-Bebber R, King MT, Boxer MM et al (2017) What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions? Breast Cancer 24(5):720\u2013729","journal-title":"Breast Cancer"},{"issue":"22","key":"6488_CR20","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1200\/JCO.2005.11.692","volume":"23","author":"JA Hayman","year":"2005","unstructured":"Hayman JA, Kabeto MU, Schipper MJ, Bennett JE, Vicini FA, Pierce LJ (2005) Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. J Clin Oncol 23(22):5171\u20135177","journal-title":"J Clin Oncol"},{"issue":"10","key":"6488_CR21","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1245\/s10434-015-4740-8","volume":"22","author":"P Subhedar","year":"2015","unstructured":"Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ (2015) Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 22(10):3273\u20133281","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"6488_CR22","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1245\/s10434-019-07423-7","volume":"26","author":"RFD van la Parra","year":"2019","unstructured":"van la Parra RFD, Clough KB, Lejalle-Alaeddine C, Poulet B, Sarfati I, Nos C (2019) Oncoplastic level 2 mammoplasty for large DCIS: 5-year results. Ann Surg Oncol 26(8):2459\u20132465","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"6488_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/jnci\/djaa179","volume":"113","author":"E Rakovitch","year":"2021","unstructured":"Rakovitch E, Sutradhar R, Nofech-Mozes S et al (2021) 21-gene assay and breast cancer mortality in ductal carcinoma in situ. J Natl Cancer Inst 113(5):572\u2013579","journal-title":"J Natl Cancer Inst"},{"issue":"3S","key":"6488_CR24","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.ijrobp.2021.07.104","volume":"111","author":"FA Vicini","year":"2021","unstructured":"Vicini FA, Shah CS, Whitworth PW et al (2021) Biosignatures to optimize adjuvant radiation therapy use in patients with DCIS with high risk clinicopathologic features. Int J Radiat Oncol Biol Phys 111(3S):S34\u2013S35","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"6488_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.prro.2016.06.011","volume":"6","author":"M Morrow","year":"2016","unstructured":"Morrow M, Van Zee KJ, Solin LJ et al (2016) Society of surgical oncology-american society for radiation oncology-american society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol 6(5):287\u2013295","journal-title":"Pract Radiat Oncol"},{"issue":"9169","key":"6488_CR26","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 353(9169):1993\u20132000","journal-title":"Lancet"},{"issue":"10021","key":"6488_CR27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","volume":"387","author":"JF Forbes","year":"2016","unstructured":"Forbes JF, Sestak I, Howell A et al (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 387(10021):866\u2013873","journal-title":"Lancet"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06488-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T16:07:19Z","timestamp":1644768439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06488-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6488"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06488-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E Rakovitch has received research grant funding from Genomic Health Inc. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Research ethics board approval obtained from Sunnybrook Health Sciences Centre, Toronto, Ontario.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This is a population-based retrospective analysis. All personal identifiers for each case in this population cohort were removed. This study was facilitated through ICES which is named as a prescribed entity in section\u00a045 of PHIPA (Regulation 329\/04, section\u00a018) which allows access and utilization of administrative data for research purposes with a waived requirement for consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}